288 related articles for article (PubMed ID: 26820618)
1. Everolimus Initiation With Early Calcineurin Inhibitor Withdrawal in De Novo Heart Transplant Recipients: Three-Year Results From the Randomized SCHEDULE Study.
Andreassen AK; Andersson B; Gustafsson F; Eiskjaer H; Rådegran G; Gude E; Jansson K; Solbu D; Karason K; Arora S; Dellgren G; Gullestad L;
Am J Transplant; 2016 Apr; 16(4):1238-47. PubMed ID: 26820618
[TBL] [Abstract][Full Text] [Related]
2. The Effect of Everolimus Initiation and Calcineurin Inhibitor Elimination on Cardiac Allograft Vasculopathy in De Novo Recipients: One-Year Results of a Scandinavian Randomized Trial.
Arora S; Andreassen AK; Andersson B; Gustafsson F; Eiskjaer H; Bøtker HE; Rådegran G; Gude E; Ioanes D; Solbu D; Sigurdardottir V; Dellgren G; Erikstad I; Solberg OG; Ueland T; Aukrust P; Gullestad L;
Am J Transplant; 2015 Jul; 15(7):1967-75. PubMed ID: 25783974
[TBL] [Abstract][Full Text] [Related]
3. Everolimus Initiation With Early Calcineurin Inhibitor Withdrawal in De Novo Heart Transplant Recipients: Long-term Follow-up From the Randomized SCHEDULE Study.
Gustafsson F; Andreassen AK; Andersson B; Eiskjær H; Rådegran G; Gude E; Jansson K; Solbu D; Karason K; Arora S; Dellgren G; Gullestad L;
Transplantation; 2020 Jan; 104(1):154-164. PubMed ID: 30893292
[TBL] [Abstract][Full Text] [Related]
4. Five-year outcomes in kidney transplant patients randomized to everolimus with cyclosporine withdrawal or low-exposure cyclosporine versus standard therapy.
Sommerer C; Duerr M; Witzke O; Lehner F; Arns W; Kliem V; Ackermann D; Guba M; Jacobi J; Hauser IA; Stahl R; Reinke P; Rath T; Veit J; Mehrabi A; Porstner M; Budde K;
Am J Transplant; 2018 Dec; 18(12):2965-2976. PubMed ID: 29722128
[TBL] [Abstract][Full Text] [Related]
5. Everolimus with cyclosporine withdrawal or low-exposure cyclosporine in kidney transplantation from Month 3: a multicentre, randomized trial.
Budde K; Zeier M; Witzke O; Arns W; Lehner F; Guba M; Jacobi J; Kliem V; Reinke P; Hauser IA; Vogt B; Stahl R; Rath T; Duerr M; Paulus EM; May C; Porstner M; Sommerer C;
Nephrol Dial Transplant; 2017 Jun; 32(6):1060-1070. PubMed ID: 28605781
[TBL] [Abstract][Full Text] [Related]
6. Two-year outcomes in de novo renal transplant recipients receiving everolimus-facilitated calcineurin inhibitor reduction regimen from the TRANSFORM study.
Berger SP; Sommerer C; Witzke O; Tedesco H; Chadban S; Mulgaonkar S; Qazi Y; de Fijter JW; Oppenheimer F; Cruzado JM; Watarai Y; Massari P; Legendre C; Citterio F; Henry M; Srinivas TR; Vincenti F; Gutierrez MPH; Marti AM; Bernhardt P; Pascual J;
Am J Transplant; 2019 Nov; 19(11):3018-3034. PubMed ID: 31152476
[TBL] [Abstract][Full Text] [Related]
7. Early conversion from cyclosporine to everolimus following living-donor kidney transplantation: outcomes at 5 years posttransplant in the randomized ZEUS trial.
Sommerer C; Budde K; Zeier M; Wüthrich RP; Reinke P; Eisenberger U; Mühlfeld A; Arns W; Stahl R; Heller K; Wolters HH; Suwelack B; Klehr HU; Hauser IA; Stangl M; Nadalin S; Dürr M; Porstner M; May C; Wimmer P; Witzke O; Lehner F
Clin Nephrol; 2016 Apr; 85(4):215-25. PubMed ID: 26932178
[TBL] [Abstract][Full Text] [Related]
8. Everolimus and early calcineurin inhibitor withdrawal: 3-year results from a randomized trial in liver transplantation.
Sterneck M; Kaiser GM; Heyne N; Richter N; Rauchfuss F; Pascher A; Schemmer P; Fischer L; Klein CG; Nadalin S; Lehner F; Settmacher U; Neuhaus P; Gotthardt D; Loss M; Ladenburger S; Paulus EM; Mertens M; Schlitt HJ
Am J Transplant; 2014 Mar; 14(3):701-10. PubMed ID: 24502384
[TBL] [Abstract][Full Text] [Related]
9. Conversion from everolimus with low-exposure cyclosporine to everolimus with mycophenolate sodium maintenance therapy in kidney transplant recipients: a randomized, open-label multicenter study.
Albano L; Alamartine E; Toupance O; Moulin B; Merville P; Rerolle JP; Tetaz R; Moal MC; Kamar N; Legendre C; Quéré S; Di Giambattista F; Terpereau A; Dantal J
Ann Transplant; 2012; 17(1):58-67. PubMed ID: 22466910
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Everolimus and Mycophenolic Acid With Early Tacrolimus Withdrawal After Liver Transplantation: A Multicenter Randomized Trial.
Saliba F; Duvoux C; Gugenheim J; Kamar N; Dharancy S; Salamé E; Neau-Cransac M; Durand F; Houssel-Debry P; Vanlemmens C; Pageaux G; Hardwigsen J; Eyraud D; Calmus Y; Di Giambattista F; Dumortier J; Conti F
Am J Transplant; 2017 Jul; 17(7):1843-1852. PubMed ID: 28133906
[TBL] [Abstract][Full Text] [Related]
11. Everolimus with Reduced Calcineurin Inhibitor Exposure in Renal Transplantation.
Pascual J; Berger SP; Witzke O; Tedesco H; Mulgaonkar S; Qazi Y; Chadban S; Oppenheimer F; Sommerer C; Oberbauer R; Watarai Y; Legendre C; Citterio F; Henry M; Srinivas TR; Luo WL; Marti A; Bernhardt P; Vincenti F;
J Am Soc Nephrol; 2018 Jul; 29(7):1979-1991. PubMed ID: 29752413
[No Abstract] [Full Text] [Related]
12. Effect of Everolimus Initiation and Calcineurin Inhibitor Elimination on Cardiac Allograft Vasculopathy in De Novo Heart Transplant Recipients.
Arora S; Andreassen AK; Karason K; Gustafsson F; Eiskjær H; Bøtker HE; Rådegran G; Gude E; Ioanes D; Solbu D; Dellgren G; Ueland T; Aukrust P; Gullestad L;
Circ Heart Fail; 2018 Sep; 11(9):e004050. PubMed ID: 30354362
[TBL] [Abstract][Full Text] [Related]
13. Calcineurin inhibitor-free immunosuppression in pediatric renal transplantation: a viable option?
Höcker B; Tönshoff B
Paediatr Drugs; 2011 Feb; 13(1):49-69. PubMed ID: 21162600
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of the early introduction of everolimus with reduced-exposure cyclosporine a in de novo kidney recipients.
Oh CK; Huh KH; Ha J; Kim YH; Kim YL; Kim YS
Transplantation; 2015 Jan; 99(1):180-6. PubMed ID: 24983307
[TBL] [Abstract][Full Text] [Related]
15. Long-term outcomes of thoracic transplant recipients following conversion to everolimus with reduced calcineurin inhibitor in a multicenter, open-label, randomized trial.
Gullestad L; Eiskjaer H; Gustafsson F; Riise GC; Karason K; Dellgren G; Rådegran G; Hansson L; Gude E; Bjørtuft Ø; Jansson K; Schultz HH; Solbu D; Iversen M
Transpl Int; 2016 Jul; 29(7):819-29. PubMed ID: 27067532
[TBL] [Abstract][Full Text] [Related]
16. Early Conversion From Calcineurin Inhibitor- to Everolimus-Based Therapy Following Kidney Transplantation: Results of the Randomized ELEVATE Trial.
de Fijter JW; Holdaas H; Øyen O; Sanders JS; Sundar S; Bemelman FJ; Sommerer C; Pascual J; Avihingsanon Y; Pongskul C; Oppenheimer F; Toselli L; Russ G; Wang Z; Lopez P; Kochuparampil J; Cruzado JM; van der Giet M;
Am J Transplant; 2017 Jul; 17(7):1853-1867. PubMed ID: 28027625
[TBL] [Abstract][Full Text] [Related]
17. Five-year outcomes in kidney transplant patients converted from cyclosporine to everolimus: the randomized ZEUS study.
Budde K; Lehner F; Sommerer C; Reinke P; Arns W; Eisenberger U; Wüthrich RP; Mühlfeld A; Heller K; Porstner M; Veit J; Paulus EM; Witzke O;
Am J Transplant; 2015 Jan; 15(1):119-28. PubMed ID: 25521535
[TBL] [Abstract][Full Text] [Related]
18. Everolimus initiation and early calcineurin inhibitor withdrawal in heart transplant recipients: a randomized trial.
Andreassen AK; Andersson B; Gustafsson F; Eiskjaer H; Radegran G; Gude E; Jansson K; Solbu D; Sigurdardottir V; Arora S; Dellgren G; Gullestad L;
Am J Transplant; 2014 Aug; 14(8):1828-38. PubMed ID: 25041227
[TBL] [Abstract][Full Text] [Related]
19. A randomized trial of everolimus-based quadruple therapy vs standard triple therapy early after lung transplantation.
Gottlieb J; Neurohr C; Müller-Quernheim J; Wirtz H; Sill B; Wilkens H; Bessa V; Knosalla C; Porstner M; Capusan C; Strüber M
Am J Transplant; 2019 Jun; 19(6):1759-1769. PubMed ID: 30615259
[TBL] [Abstract][Full Text] [Related]
20. Everolimus Versus Mycophenolate Mofetil De Novo After Lung Transplantation: A Prospective, Randomized, Open-Label Trial.
Strueber M; Warnecke G; Fuge J; Simon AR; Zhang R; Welte T; Haverich A; Gottlieb J
Am J Transplant; 2016 Nov; 16(11):3171-3180. PubMed ID: 27104933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
